Bariatric surgery, the primary treatment for class II or III obesity, is among the safest surgical procedures worldwide, with extensive long-term data demonstrating sustained efficacy across diverse populations. Meanwhile, GLP-1RA therapies are approaching the efficacy of surgery. Phase III trials of new GLP-1–based therapies underscore their efficacy, resulting in weight loss of up to 25% within 1 year of treatment. As a result, there is an opportunity to implement a more personalized approach to obesity treatment through a comprehensive multidisciplinary evaluation that considers surgical, medical, and combined therapies, ultimately leading to improved and sustained outcomes.